Scancell Holdings plc (LON:SCLP – Get Free Report)’s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 10.56 ($0.14) and traded as high as GBX 14.50 ($0.19). Scancell shares last traded at GBX 14.25 ($0.18), with a volume of 1,130,416 shares.
Scancell Price Performance
The company has a 50-day simple moving average of GBX 10.80 and a 200-day simple moving average of GBX 10.56. The stock has a market cap of £132.38 million, a PE ratio of -1,425.00 and a beta of 0.37. The company has a debt-to-equity ratio of 61.41, a current ratio of 8.63 and a quick ratio of 13.01.
Scancell Company Profile
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer.
Further Reading
- Five stocks we like better than Scancell
- Do ETFs Pay Dividends? What You Need to Know
- Is Crypto Cool Again? What Stocks You Should Be Watching
- Consumer Staples Stocks, Explained
- Why Call Options Volume for These 2 Stocks Spiked Together
- Dividend Capture Strategy: What You Need to Know
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
